Dinutuximab

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 220 publications

Concurrent Treatment With Lorlatinib and Dinutuximab Beta Induced Acute Gastric Dilation in a Pediatric Patient With Neuroblastoma.

Concurrent Treatment With Lorlatinib and Dinutuximab Beta Induced Acute Gastric Dilation in a Pediatric Patient With Neuroblastoma.

Journal: Pediatric blood & cancer

Published: July 27, 2026

Circumventing Ewing sarcoma tumor microenvironment resistance by IL1RAP CAR-modified TGFβ1-imprinted natural killer cells in combination with IL-15 agonist and anti-GD2 antibody.

Circumventing Ewing sarcoma tumor microenvironment resistance by IL1RAP CAR-modified TGFβ1-imprinted natural killer cells in combination with IL-15 agonist and anti-GD2 antibody.

Journal: Journal for immunotherapy of cancer

Published: June 24, 2026

GD2-targeted immunotherapy in pediatric bone sarcomas: a systematic review of emerging strategies and combination approaches.

GD2-targeted immunotherapy in pediatric bone sarcomas: a systematic review of emerging strategies and combination approaches.

Journal: Frontiers in immunology

Published: May 29, 2026

Tislelizumab combined with Anti-GD2 antibody-based chemoimmunotherapy for pediatric relapsed/refractory high-risk neuroblastoma: a two-Case Report.

Tislelizumab combined with Anti-GD2 antibody-based chemoimmunotherapy for pediatric relapsed/refractory high-risk neuroblastoma: a two-Case Report.

Journal: Frontiers in pharmacology

Published: May 25, 2026

Dinutuximab beta with TEMIRI chemotherapy in relapsed/refractory neuroblastoma: Real-world insights into the open question of GD2 expression.

Dinutuximab beta with TEMIRI chemotherapy in relapsed/refractory neuroblastoma: Real-world insights into the open question of GD2 expression.

Journal: Translational oncology

Published: May 18, 2026

Association Between Dinutuximab Beta Exposure and Post-End-of-Treatment Survival in Neuroblastoma: A Weighted Patient-Level Analysis of Three Clinical Studies.

Association Between Dinutuximab Beta Exposure and Post-End-of-Treatment Survival in Neuroblastoma: A Weighted Patient-Level Analysis of Three Clinical Studies.

Journal: Pediatric blood & cancer

Published: May 10, 2026

Combination Therapy with Pregabalin and Morphine Relieves Dinutuximab-Induced Pain in a 3-Year-Old Girl: A Case Report.

Combination Therapy with Pregabalin and Morphine Relieves Dinutuximab-Induced Pain in a 3-Year-Old Girl: A Case Report.

Journal: Palliative medicine reports

Published: May 04, 2026

Management of persistent soft tissue residuals exhibiting an imaging paradox (^123I-MIBG-negative/^68Ga-DOTA-NOC-positive) in high-risk neuroblastoma following immunotherapy: a case report.

Management of persistent soft tissue residuals exhibiting an imaging paradox (^123I-MIBG-negative/^68Ga-DOTA-NOC-positive) in high-risk neuroblastoma following immunotherapy: a case report.

Journal: Frontiers in immunology

Published: April 28, 2026

Role of Anti-GD2 Targeted PEG-b-PLGA Nanoparticles in the Treatment of MYCN Driven Neuroblastoma.

Role of Anti-GD2 Targeted PEG-b-PLGA Nanoparticles in the Treatment of MYCN Driven Neuroblastoma.

Journal: ACS applied bio materials

Published: April 02, 2026

Immunotherapeutic Strategies Targeting GD2-Expressing Malignancies.

Immunotherapeutic Strategies Targeting GD2-Expressing Malignancies.

Journal: Advances in experimental medicine and biology

Published: March 31, 2026

Impacts of Globo H Ceramide on Tumor Microenvironment.

Impacts of Globo H Ceramide on Tumor Microenvironment.

Journal: Advances in experimental medicine and biology

Published: March 31, 2026

Efficacy of anti-GD2 antibody immunotherapy with filgrastim and teceleukin versus standard treatment with sargramostim, aldesleukin and isotretinoin in children with high-risk neuroblastoma.

Efficacy of anti-GD2 antibody immunotherapy with filgrastim and teceleukin versus standard treatment with sargramostim, aldesleukin and isotretinoin in children with high-risk neuroblastoma.

Journal: International journal of clinical oncology

Published: March 18, 2026

Showing 1-12 of 220

Last Updated: 09/26/2026